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Abstract 40 
(199 words) 41 
Clinical prediction models combine multiple predictors to estimate the risk of whether a particular 42 
condition is present (diagnostic) or whether a certain event will occur in the future (prognostic). 43 
PROBAST, a tool for assessing the risk of bias (ROB) and applicability of diagnostic and prognostic 44 
prediction model studies, considered existing ROB tools as well as reporting guidelines and was 45 
developed by a steering group, informed by a Delphi procedure involving 38 experts and refinement 46 
through piloting. 47 
PROBAST is grouped into four domains: participants, predictors, outcomes, and analysis. These 48 
domains contain a total of twenty signalling questions to facilitate structured judgement of ROB. We 49 
define ROB to occur when shortcomings in study design, conduct or analysis lead to systematically 50 
distorted estimates of model predictive performance. PROBAST enables a focussed and transparent 51 
approach to assessing the ROB and applicability of studies developing, validating or 52 
updating prediction models for individualised predictions. 53 
Although PROBAST was designed for use in systematic reviews, it can be used more generally in critical 54 
appraisal of prediction model studies. Potential users include organisations supporting decision 55 
making, researchers and clinicians with an interest in evidence-based medicine or involved in guideline 56 
development as well as journal editors and manuscript reviewers.  57 
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Introduction  58 
(546 words) 59 
Prediction relates to estimating the probability of something currently unknown. In the context of 60 
medical research, prediction typically relates to either diagnosis (probability of a certain condition 61 
being present but not yet detected) or prognosis (probability of developing a future outcome).(1-3) 62 
Prognosis does not only apply to sick individuals or those with an established diagnosis, but also to, for 63 
example, prognosis of pregnant women at risk of developing diabetes.(4) Prediction research includes 64 
predictor finding studies, prediction model studies (development, validation and extending or 65 
updating), and prediction model impact studies.(1) 66 
Predictor finding studies (also known as risk factor or prognostic factor studies) aim to identify which 67 
predictors (e.g. age, disease stage, biomarkers) independently contribute to the prediction of a 68 
diagnostic or prognostic outcome.(1, 5) 69 
Prediction model studies typically aim to develop, validate or update (e.g. extend) a multivariable 70 
prediction model. In a prediction model, multiple predictors are used in combination for estimating 71 
probabilities to inform and often guide individual care.(2, 6, 7) These models can either predict an 72 
individual’s probability of currently having a particular outcome or disease (diagnostic prediction 73 
model) or experiencing a particular outcome in the future (prognostic prediction model). Prediction 74 
models, both diagnostic and prognostic, are widely used for a variety of medical domains and 75 
settings,(8-10) evidenced by the large number of models developed, especially in cancer,(11, 12) 76 
neurology,(13, 14) and cardiovascular disease domains.(15) Prediction models are sometimes 77 
described as risk prediction models, predictive models, prediction indices or rules, or risk scores.(2, 7) 78 
An example is QRISK2 for predicting cardiovascular risk.(16)  79 
Prediction model impact studies evaluate the effect of using a model to guide patient care compared 80 
to not using such a model, and focus on the effect of its use on clinical decision making, patient 81 
outcomes, or costs of care, using a comparative design such as a randomised trial.(1) 82 
Systematic reviews have a key role in evidence-based medicine and in the development of clinical 83 
guidelines.(17-19) They are considered to provide the most reliable form of evidence for the effects of 84 
an intervention or diagnostic test.(20, 21) Systematic reviews of prediction models are a relatively new 85 
and evolving area but are increasingly undertaken to systematically identify, appraise and summarise 86 
evidence on the performance of prediction models.(1, 6, 22)  87 
Quality assessment of included studies is a crucial step in any systematic review.(20, 21) The QUIPS tool 88 
has been developed to assess the risk of bias (ROB) in predictor finding (prognostic factor) studies.(23) 89 
The methodological quality of studies investigating the impact of a prediction model using a 90 
comparative randomised design can be assessed using the revised Cochrane ROB tool (ROB 2.0)(24) or 91 
ROBINS-I for non-randomised comparative designs.(25) With the increased number of prediction 92 
model studies as well as systematic reviews of prediction model studies, a tool facilitating quality 93 
assessment for individual prediction model studies is urgently needed. 94 
We present PROBAST (Prediction model Risk Of Bias ASsessment Tool), a tool to assess the ROB and 95 
concerns regarding the applicability of diagnostic and prognostic prediction model studies. PROBAST 96 
can be used to assess both model development and model validation studies, including those updating 97 
a prediction model (Box 1). We explicitly refer to the accompanying Explanation and Elaboration paper 98 
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for detailed explanations on how to use the PROBAST tool and how to make ROB and applicability 99 
judgements.[REF M18-1377]  100 
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Methods – Development of PROBAST 101 
(813 words) 102 
Development of PROBAST was based on a four-stage approach for developing health research 103 
reporting guidelines: define the scope, review the evidence base, web-based Delphi procedure, and 104 
refine the tool through piloting.(27) Guidelines explicitly aimed at the development of quality 105 
assessment tools were not available at the time.(28) 106 
Development stage 1: Scope and Definitions 107 
A steering group of nine experts in the area of prediction model studies and quality assessment tool 108 
development agreed on key features of the desired scope of PROBAST. The scope was further refined 109 
during the web-based Delphi procedure with a panel of 38 experts with different backgrounds. 110 
PROBAST was primarily designed to assess primary studies included in a systematic review. The group 111 
agreed that PROBAST would assess both, the risk of bias and concerns regarding applicability, of a 112 
study evaluating a multivariable diagnostic or prognostic prediction model to be used for individualised 113 
predictions. A domain-based structure was adopted similar to that used in other risk of bias tools such 114 
as ROB 2.0,(24) ROBINS-I,(25) QUADAS-2,(29) and ROBIS.(30) 115 
It was agreed that PROBAST should cover primary studies that developed, validated or updated one or 116 
more multivariable prediction models for the purpose of making individualised predictions of a 117 
diagnostic or prognostic outcome (Box 1). Studies using multivariable modelling techniques to identify 118 
predictors (e.g. risk or prognostic factors) associated with an outcome but not attempting to develop, 119 
validate or update a model for making individualised predictions are not covered by PROBAST.(5) 120 
Therefore, PROBAST is not intended for predictor finding studies and prediction model impact studies. 121 
Diagnostic and prognostic model studies often use different terms for the predictors and 122 
outcomes (Box 2). A multivariable prediction model is defined as any combination or equation of two 123 
or more predictors for estimating the probability or risk for an individual.(6, 7, 31-33) 124 
Development stage 2: Review of Evidence 125 
Three different approaches were used to provide an evidence base to inform the development of 126 
PROBAST: (1) identification of relevant methodological reviews in the area of prediction model 127 
research (November 2012 to January 2013), (2) asking members of the steering group to identify 128 
relevant methodological studies (January 2013 to March 2013), and (3) use of the Delphi procedure to 129 
ask members of the wider group to identify additional evidence (February 2012 to July 2014). 130 
Identified literature was used to guide the scope and produce an initial list of signalling questions for 131 
consideration for inclusion in PROBAST.(1, 2, 5-7, 26, 32-39) Signalling questions were grouped into 132 
common themes in order to identify possible domains.  Additional literature provided as part of the 133 
web-based surveys was used to inform the development of the E&E paper. 134 
Development stage 3: Web-based Delphi procedure 135 
A modified Delphi process was used to gain feedback and agreement on the scope, structure and 136 
content of PROBAST. Web-based surveys were developed to gather structured feedback for each 137 
round. The Delphi group included 38 members comprising methodological experts in the areas of 138 
prediction model research and quality assessment tool development, experienced systematic 139 
reviewers, commissioners, and representatives of reimbursements agencies. Different potential 140 
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stakeholders were included to ensure that the views of end-users, methodological experts and decision 141 
makers were represented. 142 
The Delphi process consisted of seven rounds. Round 1 asked about the scope of the tool and it was 143 
agreed to focus on prediction model studies only and to follow a domain-based structure. Round 2 144 
aimed at identifying and finding a consensus regarding the relevant domains to be included. The 145 
signalling questions for domains were refined in rounds 3 to 5. Respondents were asked to rate each 146 
proposed signalling question for inclusion using a 1 to 5 Likert scale. They were also given the 147 
opportunity to provide suggested rephrasing, provide any supporting evidence (e.g. references to 148 
relevant studies) and suggest any missing signalling questions. Round 6 refined the domains and 149 
introduced further optional guidance for the use of PROBAST. In the last round, participants were sent 150 
the agreed draft version of PROBAST and given the opportunity to provide any final feedback. 151 
Development stage 4: Piloting and refining of the tool 152 
Six workshops on PROBAST were held at consecutive annual Cochrane Colloquia (Quebec 2013, 153 
Hyderabad 2014, Vienna 2015, Seoul 2016, Cape Town 2017, Edinburgh 2018) and numerous 154 
consecutive workshops with MSc and PhD students (e.g. MSc Epidemiology program of Utrecht 155 
University, The Netherlands, and Evidence Based Health Care program of Oxford University, UK). In 156 
these, we piloted the then current version of the PROBAST tool to gather feedback on the practical 157 
issues associated with using the tool so we could further refine and subsequently validate the tool. 158 
Finally, over fifty review groups have already piloted PROBAST versions, included the final version, in 159 
their reviews. Topics included cancer, cardiology, endocrinology, pulmonology and orthopaedics. 160 
All feedback received from these initiatives was used to further inform the content and structure of 161 
the PROBAST tool, wording of the signalling questions, and content of the guidance documents.[REF 162 
M18-1377]  163 
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Results – The PROBAST tool 164 
(1,640 words) 165 
What does PROBAST assess? 166 
PROBAST assesses both the risk of bias and concerns regarding applicability of primary studies that 167 
developed or validated one or more multivariable prediction models for diagnosis or 168 
prognosis (Boxes 1 and 2). 169 
Development of a prediction model can include adding new predictors to an existing prediction model. 170 
Similarly, validation of an existing model can be accompanied by updating and also extending of the 171 
model, i.e. the development of a new model. PROBAST is applicable to both situations (Box 1). 172 
Target users 173 
Although PROBAST was designed for use in systematic reviews, it can be used more generally in critical 174 
appraisal of prediction model studies. Potential users of PROBAST include organisations supporting 175 
decision making (e.g. National Institute for Health and Care Excellence, NICE; Institute for Quality and 176 
Efficiency in Health Care, IQWiG), researchers and clinicians with an interest in evidence-based 177 
medicine or involved in guideline development as well as journal editors, manuscript reviewers and 178 
readers wanting to critically appraise prediction model studies. 179 
Definition of risk of bias and applicability 180 
Bias is usually defined as presence of systematic error within a study leading to distorted or flawed 181 
study results, hampering the internal validity of that study. In prediction model development and 182 
validation, there are known features which make a study at ROB, although there is limited empirical 183 
evidence to demonstrate the most important sources of bias. We define risk of bias to occur when 184 
shortcomings in the study design, conduct or analysis lead to systematically distorted estimates of 185 
model predictive performance. Model predictive performance is typically evaluated using measures of 186 
calibration and discrimination, and sometimes (notably in diagnostic model studies) classification.(7) 187 
To understand bias in study estimates of model predictive performance, it helps to think about how a 188 
hypothetical methodologically robust prediction model study would have been designed, conducted 189 
and analysed. Many sources of bias identified in other medical research areas are also relevant to 190 
prediction model studies, such as blinding of assessors of study outcomes to other features of the 191 
study, and the use of consistent definitions and measurements for predictors and outcomes within the 192 
study. 193 
Concerns regarding the applicability of primary studies to the review question can arise when the study 194 
population, predictors or outcomes of a primary study differ from those specified in the review 195 
question. Applicability concerns may arise when participants in the prediction model study are from a 196 
different medical setting than the population defined in the review question. For example, participants 197 
in a primary prediction model study may be enrolled from a hospital setting but the review question 198 
specifically relates to participants in primary care. The reported prediction model discrimination and 199 
calibration may not be applicable, as patients in hospital settings typically have more severe disease 200 
than patients in primary care.(40, 41) 201 
For systematic reviews where eligibility criteria, predictors and outcomes of the primary studies, 202 
directly match the review question, there will be no concerns for applicability of a primary study for 203 
the review. However, typically systematic reviews have inclusion criteria that are broader than the 204 
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focus of the review question. The broader inclusion criteria allow for variation in the searching of the 205 
primary studies and thus require careful assessment of applicability of each primary study to the actual 206 
review question.(7)[REF M18-1377] 207 
Types of prediction model study 208 
A primary study identified as relevant for the review may include the development, validation or 209 
update of one or more prediction models. For each study, a PROBAST assessment should be completed 210 
for each distinct model that is developed, validated, or updated for making individualised predictions, 211 
relevant to the systematic review question. 212 
PROBAST includes four steps (Table 1). We stress the importance of the accompanying paper which 213 
provides detailed explanations and guidance for completing each step.[REF M18-1377] 214 
Step 1: Specify your systematic review question 215 
Assessors are first asked to report their systematic review question in terms of intended use of the 216 
model, targeted participants, predictors used in the modelling, and predicted outcome. Specific 217 
guidance (i.e. the CHARMS checklist) exists to help reviewers define a clear and focused review 218 
question.(22, 26) 219 
Step 2: Classify the type of prediction model evaluation 220 
Different signalling questions apply for different types of prediction model evaluation. For each model 221 
assessment, reviewers classify a model as “development only”, “development and validation in the 222 
same publication” or “validation only”. When a publication focuses on creating a model by adding one 223 
or more new predictors to established predictors (or an established model), “development only” 224 
should be used. When a publication focuses on validation of an existing model in other data though 225 
followed by updating (adjusting or extending) of the model such that in fact a new model is being 226 
developed, then “development and validation in the same publication” should be used. Note again 227 
that sometimes a single publication may address more than one model of interest. 228 
Step 3: Assess risk of bias and applicability 229 
Step 3 aims to identify areas where bias may be introduced into the prediction model study or where 230 
there may be concerns for applicability. It involves the assessment of four domains to cover key aspects 231 
of prediction model studies: (1) participants, (2) predictors, (3) outcome, and (4) analysis. The risk of 232 
bias component of each domain comprises four sections: information used to support the judgment, 233 
20 signalling questions (2 to 9 per domain), judgment of ROB, and rationale regarding the 234 
judgment (Table 2) 235 
The support for judgement box provides space to record the information used to answer the signalling 236 
questions. Signalling questions are rated as yes (Y), probably yes (PY), probably no (PN), no (N) or no 237 
information (NI). Risk of bias is judged as “low”, “high”, or “unclear”. All signalling questions are 238 
phrased so that “yes” indicates absence of bias. Any signalling question rated as “no” or “probably no” 239 
flags the potential for bias; assessors will need to use their own judgment to determine whether the 240 
domain should be rated as “high”, “low” or “unclear” risk of bias. A “no” rating does not automatically 241 
result in a “high” risk of bias rating. The “no information” category should be used only when 242 
insufficient information is reported to permit a judgment. By recording the rationale for the risk of bias 243 
rating, the rating will be transparent and, where necessary, facilitate discussion among review authors 244 
completing assessments independently. 245 
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The first three domains are also rated for concerns regarding applicability (low / high / unclear) to the 246 
review question defined above. Concerns regarding applicability are rated in a similar way to ROB but 247 
there are no signalling questions. 248 
All domains should be completed separately for each evaluation of a distinct model in each study. The 249 
team completing a PROBAST assessment is likely to need both subject content and methodological 250 
expertise to complete an assessment. For further details on how to score ROB and applicability 251 
concerns we refer to the accompanying paper and www.probast.org.[REF M18-1377] 252 
 Domain 1 (Participants) covers potential sources of bias and applicability concerns related to 253 
how participants were selected for enrolment into the study and the data sources (e.g. study 254 
designs) used. Two signalling questions support the assessment of risk of bias. 255 
 Domain 2 (Predictors) covers potential sources of bias and applicability concerns related to 256 
the definition and measurement of the predictors evaluated for inclusion in the prediction 257 
model. Three signalling questions support the assessment of risk of bias. 258 
 Domain 3 (Outcome) covers potential sources of bias and applicability concerns related to the 259 
definition and measurement of the outcome that is predicted by the model. Six signalling 260 
questions support the assessment of risk of bias. 261 
 Domain 4 (Analysis) covers potential sources of bias regarding the statistical analysis methods. 262 
It assesses aspects related to the choice of analysis method and whether key statistical 263 
considerations (e.g. in regards to missing data) were correctly addressed. Nine signalling 264 
questions support the assessment of risk of bias. 265 
Table 2 presents an overview of step 3. Detailed examples how to rate signalling questions and judge 266 
domains can be found in the E&E publication and on www.probast.org.[REF M18-1377] 267 
Step 4: Overall judgement 268 
Based on the risk of bias classifications for each domain in step 3, an overall judgement about ROB of 269 
the prediction model should be made. An overall rating of either low, high, or unclear ROB should be 270 
used. We recommend rating the prediction model to be of a low ROB if no relevant shortcomings were 271 
identified in the risk of bias assessment, i.e. all domains were rated as “low risk of bias”. If at least one 272 
domain was judged to be of high ROB, an overall judgement of high ROB should be used. Similarly, 273 
unclear ROB should be assigned once an unclear ROB was noted in at least one domain and it was low 274 
risk for all other domains. 275 
However, if a prediction model was developed without any external validation on different participants 276 
and even all four domains were rated as low ROB, downgrading to high ROB should still be considered 277 
unless the model development was based on a very large data set or included some form of internal 278 
validation. For details we refer to the E&E paper.[REF M18-1377] 279 
Based on the applicability classifications for each domain in step 3, an overall judgement about the 280 
concerns regarding applicability of the prediction model is needed. A “low concern” decision should 281 
only be reached if all domains showed low concerns regarding applicability. Similarly, if one or more 282 
domains were judged to have high concerns regarding applicability, the overall judgement should be 283 
“high concern”. “Unclear concerns regarding applicability” should only be reached if one or more 284 
domains are judged as “unclear” regarding applicability and all other domains were rated to have “low 285 
concerns”. 286 
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Detailed explanation and examples on how to judge the overall ROB and concerns regarding 287 
applicability can be found in the accompanying publication and on www.probast.org.[REF M18-1377] 288 
Table 3 suggests a way to present the results of the PROBAST assessments.  289 
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Discussion 290 
[331 words] 291 
Assessment of the quality of included studies is an essential component of all systematic reviews and 292 
evidence syntheses. Systematic reviews of prediction model studies are a rapidly evolving area.(22) 293 
With the increased number of prediction model studies as well as systematic reviews of prediction 294 
model studies, a tool facilitating quality assessment for individual prediction model studies is urgently 295 
needed. PROBAST is the first rigorously developed tool designed specifically to assess the quality of 296 
prediction model studies for development, validation or updating models for both diagnostic and 297 
prognostic models, regardless of the medical domain, type of outcome, predictors or statistical 298 
technique used. 299 
We adopted a domain based structure similar to that used in other recently developed tools such as 300 
the revised Cochrane risk of bias tool (ROB 2.0),(24) QUADAS-2 for diagnostic accuracy studies,(29) 301 
ROBINS-I for non-randomised studies,(25) and ROBIS for systematic reviews.(30) All stages of PROBAST 302 
development included a wide range of stakeholders with piloting starting with early versions of the 303 
tool allowing feedback from direct reviewer experience to be incorporated into the final tool. We feel 304 
that these two features have resulted in a tool that is both methodologically sound and user-friendly. 305 
Potential users of PROBAST include systematic review authors, healthcare decision makers, 306 
researchers and clinicians with an interest in evidence-based medicine or involved in guideline 307 
development as well as journal editors and manuscript reviewers. 308 
Explicit guidance and explanation about how to use PROBAST is provided in the accompanying 309 
Explanation & Elaboration (E&E) paper.[REF M18-1377] To understand and use the PROBAST tool, we 310 
stress that this E&E paper should always be read in conjunction with the current paper. A 311 
multidisciplinary team, combining both subject content and methodological expertise, should be used 312 
when assessing prediction model studies. 313 
As with other risk of bias and reporting guidelines in medical research, PROBAST and its guidance will 314 
require updating, as methods for prediction model studies develop. We recommend downloading the 315 
latest version of PROBAST tool and accompanying guidance, including detailed examples from the 316 
website (www.probast.org).  317 
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Appendix 539 
The tool is also available on www.probast.org. 540 
PROBAST 541 
(Prediction model study Risk Of Bias Assessment Tool) 542 
PROBAST includes four steps. 
Step Task When to complete 
1 Specify your systematic review 
question(s) 
Once per systematic review 
2 Classify the type of prediction model 
evaluation 
Once for each model of interest in each publication 
being assessed, for each relevant outcome 
3 Assess risk of bias and applicability (per 
domain) 
Once for each development and validation of each 
distinct prediction model in a publication 
4 Overall judgment of risk of bias and 
applicability 
Once for each development and validation of each 
distinct prediction model in a publication 
 
If this is your first time using PROBAST, we strongly recommend reading the detailed explanation and 
elaboration (E&E) paper[REF M18-1377] and to check the examples on www.probast.org. 
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Step 1: Specify your systematic review question 544 
State your systematic review question to facilitate the assessment of the applicability of the evaluated 
models to your question. The following table should be completed once per systematic review. 
 545 
Criteria Specify your systematic review question 
Intended use of model:   
Participants including 
selection criteria and 
setting: 
 
Predictors (used in 
modelling) including (1) 
types of predictors (e.g. 
history, clinical 
examination, biochemical 
markers, imaging tests), 
(2) time of measurement, 
(3) specific measurement 
issues (e.g. any 
requirements/ prohibitions 
for specialised equipment): 
 
Outcome to be predicted:   
  546 
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Step 2: Classify the type of prediction model evaluation 547 
Use the following table to classify the evaluation as model development, model validation, or combination. 
Different signalling questions apply for different types of prediction model evaluation.  
When a publication focuses on adding one or more new predictors to established predictors then use 
“development only”. When a publication focuses on validation of an existing model in other data though 
followed by updating (adjusting or extending) of the model such that in fact a new model is being 
developed, then use “development and validation in the same publication”. 
If the evaluation does not fit one of these classifications then PROBAST should not be used. 
 548 









Definitions for type of prediction model study 
Development 
only 
Dev  Prediction model development without external 
validation. These studies may include internal 




Dev and Val  Prediction model development combined with 




Val  External validation of existing (previously 
developed) model in other participants  
 549 
This table should be completed once for each publication being assessed and for each relevant outcome in 
your review. 
Publication reference  
Models of interest  
Outcome of interest  
 550 
 551 
Step 3: Assess risk of bias and applicability 552 
PROBAST is structured as four key domains. Each domain is judged for risk of bias (low, high or unclear) and 
includes signalling questions to help make judgements. Signalling questions are rated as yes (Y), probably 
yes (PY), probably no (PN), no (N) or no information (NI). All signalling questions are phrased so that “yes” 
indicates absence of bias. Any signalling question rated as “no” or “probably no” flags the potential for bias; 
you will need to use your judgement to determine whether the domain should be rated as “high”, “low” or 
“unclear” risk of bias. The guidance document contains further instructions and examples on rating 
signalling questions and risk of bias for each domain. 
The first three domains are also rated for concerns for applicability (low/ high/ unclear) to your review 
question defined above.  
Complete all domains separately for each evaluation of a distinct model. Shaded boxes indicate where 
signalling questions do not apply and should not be answered. 
  553 
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DOMAIN 1: Participants 
A. Risk of Bias 
Describe the sources of data and criteria for participant selection: 
 
 
 Dev Val 
1.1 Were appropriate data sources used, e.g. cohort, RCT or nested case-control 
study data? 
  
1.2 Were all inclusions and exclusions of participants appropriate?   
Risk of bias introduced by selection of participants  
 
RISK: 
(low/ high/ unclear) 
  








Concern that the included participants and setting do not 
match the review question   
CONCERN: 
(low/ high/ unclear) 
  
Rationale of applicability rating: 
 
 
  554 
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DOMAIN 2: Predictors 
A. Risk of Bias 




 Dev Val 
2.1 Were predictors defined and assessed in a similar way for all participants?   
2.2 Were predictor assessments made without knowledge of outcome data?    
2.3 Are all predictors available at the time the model is intended to be used?   
Risk of bias introduced by predictors or their assessment RISK: 
(low/ high/ unclear) 
  




Concern that the definition, assessment or timing of 
predictors in the model do not match the review question  
CONCERN: 
(low/ high/ unclear) 
  
Rationale of applicability rating: 
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DOMAIN 3: Outcome 
A. Risk of Bias 
Describe the outcome, how it was defined and determined, and the time interval between 





 Dev Val 
3.1 Was the outcome determined appropriately?   
3.2 Was a pre-specified or standard outcome definition used?   
3.3 Were predictors excluded from the outcome definition?   
3.4 Was the outcome defined and determined in a similar way for all participants?   
3.5 Was the outcome determined without knowledge of predictor information?   
3.6 Was the time interval between predictor assessment and outcome 
determination appropriate? 
  
Risk of bias introduced by the outcome or its 
determination   
RISK: 
(low/ high/ unclear) 
  




At what time point was the outcome determined: 
 
 




Concern that the outcome, its definition, timing or 
determination do not match the review question 
CONCERN: 
(low/ high/ unclear) 
  
Rationale of applicability rating: 
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DOMAIN 4: Analysis 
Risk of Bias 
Describe numbers of participants, number of candidate predictors (for DEV only), outcome events 
and events per candidate predictor (for DEV only): 
 
 
Describe how the model was developed (predictor selection, optimism, risk groups, model performance): 
 
 
Describe whether and how the model was validated, either internally (e.g. bootstrapping, cross 
validation, random split sample) or externally (e.g. temporal validation, geographical validation, 
different setting, different type of participants): 
 
 




Describe any participants who were excluded from the analysis: 
 
 
Describe missing data on predictors and outcomes as well as methods used for missing data: 
 
 
 Dev Val 
4.1 Were there a reasonable number of participants with the outcome?   
4.2 Were continuous and categorical predictors handled appropriately?   
4.3 Were all enrolled participants included in the analysis?   
4.4 Were participants with missing data handled appropriately?   
4.5 Was selection of predictors based on univariable analysis avoided?   
4.6 Were complexities in the data (e.g. censoring, competing risks, sampling of 
controls) accounted for appropriately? 
  
4.7 Were relevant model performance measures evaluated appropriately?   
4.8 Was model overfitting and optimism in model performance accounted for?   
4.9 Do predictors and their assigned weights in the final model correspond to the 
results from the reported multivariable analysis?  
  




Rationale of bias rating: 
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Step 4: Overall assessment 558 
Use the following tables to reach overall judgements about risk of bias and concerns for applicability of the 
prediction model evaluation (development and/or validation) across all assessed domains. 
Complete for each evaluation of a distinct model. 
 
Reaching an overall judgement about risk of bias of the prediction model evaluation 
Low risk of bias  If all domains were rated low risk of bias. 
If a prediction model was developed without any external validation, and it was rated 
as low risk of bias for all domains, consider downgrading to high risk of bias. Such a 
model can only be considered as low risk of bias, if the development was based on a 
very large data set and included some form of internal validation. 
High risk of bias  If at least one domain is judged to be at high risk of bias.  
Unclear risk of 
bias 
If an unclear risk of bias was noted in at least one domain and it was low risk for all 
other domains.  
 
Reaching an overall judgement about applicability of the prediction model evaluation 
Low concerns for 
applicability  
If low concerns for applicability for all domains, the prediction model 
evaluation is judged to have low concerns for applicability. 
High concerns for 
applicability  
If high concerns for applicability for at least one domain, the prediction 
model evaluation is judged to have high concerns for applicability. 
Unclear concerns for 
applicability  
If unclear concerns (but no “high concern”) for applicability for at least one 
domain, the prediction model evaluation is judged to have unclear concerns 
for applicability overall. 
 
 559 
Overall judgement about risk of bias and applicability of the prediction model evaluation 




Summary of sources of potential bias: 
 
 




Summary of applicability concerns: 
 
 
  560 
Page 27 of 27 
 
Members of PROBAST Delphi group 561 
Members of PROBAST steering group 562 
Robert F. Wolff, Kleijnen Systematic Reviews, York, United Kingdom 563 
Karel G. M. Moons, Julius Center for Health Sciences and Primary Care and Cochrane Netherlands, UMC Utrecht, Utrecht University, The 564 
Netherlands 565 
Richard D. Riley, Keele University, United Kingdom 566 
Penny F. Whiting, University Hospitals Bristol NHS Foundation Trust, United Kingdom; University of Bristol, United Kingdom 567 
Marie Westwood, Kleijnen Systematic Reviews, York, United Kingdom 568 
Gary S. Collins, Centre for Statistics in Medicine, NDORMS, University of Oxford, United Kingdom 569 
Johannes B. Reitsma, Julius Center for Health Sciences and Primary Care and Cochrane Netherlands, UMC Utrecht, Utrecht University,  570 
The Netherlands 571 
Jos Kleijnen, Kleijnen Systematic Reviews, York, United Kingdom; School for Public Health and Primary Care (CAPHRI), Maastricht 572 
 University, Maastricht, The Netherlands 573 
Sue Mallett, Institute of Applied Health Sciences, University of Birmingham, United Kingdom 574 
Members of PROBAST Delphi group (in alphabetical order) 575 
Prof Doug Altman, PhD. Centre for Statistics in Medicine, NDORMS, University of Oxford, United Kingdom 576 
Prof Patrick Bossuyt, PhD. Division Clinical Methods & Public Health, University of Amsterdam, The Netherlands 577 
Prof Nancy R. Cook, ScD. Brigham and Women's Hospital, Boston, United States of America 578 
Gennaro D´Amico, MD. Ospedale V Cervello, Palermo, Italy 579 
Thomas P. A. Debray, PhD, MSc. Julius Center for Health Sciences and Primary Care and Cochrane Netherlands, UMC Utrecht, Utrecht 580 
University, The Netherlands 581 
Prof Jon Deeks, PhD. Institute of Applied Health Research, University of Birmingham, United Kingdom 582 
Joris de Groot, PhD. Philips Image Guided Therapy Systems, Best, The Netherlands 583 
Emanuele di Angelantonio, PhD, MSc. Department of Public Health and Primary Care, University of Cambridge, United Kingdom 584 
Prof Tom Fahey, MD, MSc. Royal College of Surgeons in Ireland, Dublin, Ireland 585 
Prof Frank Harrell, PhD. Department of Biostatistics, Vanderbilt University, United States of America 586 
Prof Jill A. Hayden, PhD. Department of Community Health and Epidemiology, Dalhousie University, Canada 587 
Martijn W. Heymans, PhD. Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, VU University 588 
Medical Center, Amsterdam, The Netherlands 589 
Lotty Hooft, PhD. Julius Center for Health Sciences and Primary Care and Cochrane Netherlands, UMC Utrecht, Utrecht University, The 590 
Netherlands 591 
Prof Chris Hyde, PhD. Institute of Health Research, University of Exeter Medical School, United Kingdom 592 
Prof John Ioannidis, MD, DSc. Meta-Research Innovation Center at Stanford (METRICS), Stanford University, United States of America 593 
Prof Alfonso Iorio, MD, PhD. Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Canada 594 
Stephen Kaptoge, PhD. Department of Public Health & Primary Care, University of Cambridge, United Kingdom 595 
Prof André Knottnerus, MD, PhD. Department of Family Medicine, Maastricht University, The Netherlands 596 
Mariska Leeflang, PHD, DVM. Department of Clinical Epidemiology, Biostatistics and Boinformatics, University of Amsterdam,  597 
The Netherlands 598 
Frances Nixon, BSc. National Institute for Health and Care Excellence (NICE), Manchester, United Kingdom 599 
Prof Pablo Perel, MD, PhD, MSc. Centre for Global Chronic Conditions, London School of Hygiene and Tropical Medicine, United Kingdom 600 
Bob Phillips, PhD, MMedSci. Centre for Reviews and Dissemination (CRD), York, United Kingdom 601 
Heike Raatz, MD, MSc. Kleijnen Systematic Reviews, York, United Kingdom 602 
Rob Riemsma, PhD. Kleijnen Systematic Reviews, York, United Kingdom 603 
Prof Maroeska Rovers, PhD. Departments of Operating Rooms and Health Evidence, Radboud University Medical Center, Nijmegen,  604 
The Netherlands 605 
Anne W. S. Rutjes, PhD, MHSc. Institute for Social and Preventive Medicine (ISPM) and Institute of Primary Health Care (BIHAM), University 606 
of Bern, Switzerland 607 
Prof Willi Sauerbrei, PhD. Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, 608 
Germany 609 
Stefan Sauerland, MD, MPH. Institute for Quality and Efficiency in Healthcare (IQWiG), Cologne, Germany 610 
Fülöp Scheibler, PhD, MA. University Medical Center Schleswig-Holstein, Kiel, Germany 611 
Prof Rob Scholten, MD, PhD. Julius Center for Health Sciences and Primary Care and Cochrane Netherlands, UMC Utrecht, Utrecht 612 
University, The Netherlands 613 
Ewoud Schuit, PhD, MSc. Julius Center for Health Sciences and Primary Care and Cochrane Netherlands, UMC Utrecht, Utrecht University, 614 
The Netherlands 615 
Prof Ewout Steyerberg, PhD. Department of Public Health, Erasmus University Medical Center Rotterdam and Department of Biomedical 616 
Data Sciences, Leiden University Medical Center, The Netherlands 617 
Toni Tan, MSc. National Institute for Health and Care Excellence (NICE), Manchester, United Kingdom 618 
Gerben ter Riet, MD, PhD. Department of General Practice, University of Amsterdam, The Netherlands 619 
Prof Danielle van der Windt, PhD. Centre for Prognosis Research, Keele University, United Kingdom 620 
Yvonne Vergouwe, PhD. Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands 621 
Andrew Vickers, PhD. Memorial Sloan-Kettering Cancer Center, New York, United States of America 622 
Angela M. Wood, PhD. Department of Public Health and Primary Care, University of Cambridge, United Kingdom 623 
Page 1 of 5 
 
PROBAST: A tool to assess the risk of bias and applicability 1 
of prediction model studies 2 
Boxes 3 
Box 1. Types of diagnostic and prognostic modelling studies or reports addressed by PROBAST 4 
(adopted from the TRIPOD and CHARMS guidance(7, 26)) 5 
Prediction model development without external validation 
These studies aim to develop one or more prognostic or diagnostic prediction models from a specific 
development data set. They aim to identify the important predictors of the outcome under study, assign 
weights (e.g. regression coefficients) to each predictor using some form of multivariable analysis, develop a 
prediction model to be used for individualised predictions, and quantify the predictive performance of that 
model in the development set. Sometimes, model development studies may also focus on adding one or more 
new predictors to established predictors. In any prediction model study, overfitting may occur, particularly in 
small data sets. Hence, development studies should include some form of resampling or "internal 
validation” (internal because the same data are used for both development and internal validation), such as 
bootstrapping or cross-validation. These methods quantify any optimism (bias) in the predictive performance 
of the developed model. 
 
Prediction model development with external validation 
Studies that have the same aim as the previous type, but the development of the model is followed by 
quantifying the model predictive performance in data external to the development sample i.e. from different 
participants. This may be data collected by the same investigators, commonly using the same predictor and 
outcome definitions and measurements, but sampled from a later time period (temporal validation); by other 
investigators in another hospital or country, sometimes using different definitions and measurements 
(geographic validation); in similar participants, but from an intentionally chosen different setting (e.g. model 
developed in secondary care and tested in similar participants from primary care); or even in other types of 
participants (e.g. model developed in adults and tested in children). Randomly splitting a single data set into 
a development and a validation data set is often erroneously referred to as a form of external validation, but 
actually is an inefficient form of "internal" validation, because the two so created data sets only differ by 
chance and sample size of model development is reduced. 
When a model predicts poorly when validated in other data, a model validation can be followed by 
adjusting (or updating the existing model (e.g. by recalibration of the baseline risk or hazard or adjusting the 
weights of the predictors in the model) to the validation data set at hand, and even by extending the model 
by adding new predictors to the existing model. In both situations in fact a new model is being developed after 
the external validation of the existing model. 
 
Prediction model external validation 
These studies aim to assess the predictive performance of one or more existing prediction models by using in 
data external to the development sample i.e. from different participants.  
  6 
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Box 2. Differences between diagnostic and prognostic prediction model studies 7 
Diagnostic prediction models aim to estimate the probability that a target condition measured using a 
reference standard (referred to as outcome in PROBAST) is currently present or absent within an individual. 
In diagnostic prediction model studies, the prediction is for an outcome already present so the preferred 
design is a cross-sectional study although sometimes follow-up is used as part of the reference test to 
determine the target condition presence at the moment of prediction. 
 
Prognostic prediction models estimate whether an individual will experience a specific event or outcome in 
the future within a certain time period, ranging from minutes to hours, days, weeks, months or years: always 
a longitudinal relationship. 
 
Despite the different timing of the predicted outcome, there are many similarities between diagnostic and 
prognostic prediction models, including the:  
 Type of outcome is often binary (target condition or disease presence (yes/no) or future occurrence 
of an outcome event (yes/no).  
 Key interest is to estimate the probability of an outcome being present or occurring in the future 
based on multiple predictors with the purpose of informing individuals and guiding decision-
making. 
 Same challenges occur when developing or validating multivariable prediction models. The same 
measures for assessing predictive performance of the model can be used, although diagnostic 
models more frequently extend assessment of predictive performance to focus on thresholds of 
clinical relevance. 
 
There are also various differences in terminology between diagnostic and prognostic model studies: 
 
Diagnostic prediction model study Prognostic prediction model study 
Predictors 
Diagnostic tests or index tests Prognostic factors or prognostic indicators 
Outcome 
Reference standard used to assess or verify 
presence/absence of target condition 
Event (future occurrence yes or no) 
Event measurement 
Missing outcome assessment 
Partial verification, lost to follow-up Lost to follow-up and censoring 
 
  8 
Page 3 of 5 
 
Tables 9 
Table 1. Four steps in PROBAST 10 
Step Task When to complete 
1 Specify your systematic review 
question(s) 
Once per systematic review 
2 Classify the type of prediction model 
evaluation 
Once for each model of interest in each 
publication being assessed, for each relevant 
outcome 
3 Assess risk of bias and applicability 
(per domain) 
Once for each development and validation of 
each distinct prediction model in a publication 
4 Overall judgment of risk of bias and 
applicability 
Once for each development and validation of 
each distinct prediction model in a publication 
.11 
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Table 2. Summary of step 3 (Assessment of risk of bias and concerns for applicability) 12 













1.1 Were appropriate data sources 
used, e.g. cohort, RCT or nested 
case-control study data? 
2.1 Were predictors defined and 
assessed in a similar way for all 
participants? 
3.1 Was the outcome determined 
appropriately? 
4.1 Were there a reasonable number of participants 
with the outcome? 
1.2 Were all inclusions and exclusions 
of participants appropriate? 
2.2 Were predictor assessments made 
without knowledge of outcome 
data? 
3.2 Was a pre-specified or standard 
outcome definition used? 
4.2 Were continuous and categorical predictors 
handled appropriately? 
 2.3 Are all predictors available at the 
time the model is intended to be 
used? 
3.3 Were predictors excluded from the 
outcome definition? 
4.3 Were all enrolled participants included in the 
analysis? 
–  3.4 Was the outcome defined and 
determined in a similar way for all 
participants? 
4.4 Were participants with missing data handled 
appropriately? 
– – 3.5 Was the outcome determined without 
knowledge of predictor information? 
4.5 Was selection of predictors based on univariable 
analysis avoided? [D] 
– – 3.6 Was the time interval between 
predictor assessment and outcome 
determination appropriate? 
4.6 Were complexities in the data (e.g. censoring, 
competing risks, sampling of controls) accounted 
for appropriately? 
– –  4.7 Were relevant model performance measures 
evaluated appropriately? 
– – – 4.8 Was model overfitting, underfitting and 
optimism in model performance accounted for? 
[D] 
– – – 4.9 Do predictors and their assigned weights in the 
final model correspond to the results from the 














Included participants and setting do 
not match the review question 
Definition, assessment or timing of 
predictors in the model do not match 
the review question 
Outcome, its definition, timing or 
determination do not match the review 
question 
– 
For further details please refer to [REF M18-1377] and www.probast.org 
Signalling questions are rated as yes (Y), probably yes (PY), probably no (PN), no (N) or no information (NI). Risk of bias and concerns for applicability are rated as low, high, or unclear. 
D = Development studies only; ROB = Risk of bias; V = Validation studies only 
13 
Page 5 of 5 
 
Table 3. Suggested Tabular Presentation for PROBAST Results 14 
Study Risk of bias Applicability Overall 
Participants Predictors Outcome Analysis Participants Predictors Outcome Risk of 
bias 
Applicability 
Study 1 + - ? + + + + - + 
Study 2 + + + + + + + + + 
Study 3 + + + ? - + + ? - 
Study 4 - ? ? - + + - - - 
Study 5 + + + + + ? + + ? 
Study 6 + + + + ? + ? + ? 
Study 7 ? ? + ? + + + ? + 
Study 8 + + + + + + + + + 
+ = low risk of bias / low concerns regarding applicability; - = high risk of bias / high concerns regarding applicability; ? = unclear risk of bias / unclear concerns regarding 
applicability 
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